Evotec bags chemical proteomics specialist Kinaxo


Hamburg-based Evotec AG is to expand its drug discovery capacity with a EUR12m acquisition. Yesterday, the company announced the purchase of private chemical proteomics specialist Kinaxo Biotechnologies GmbH. The transaction, which will cost Evotec EUR3m in cash, and EUR2.6m plus performance-based milestones up to EUR4m in cash as well EUR4m of integration costs, is expected to close in April. „Kinaxo has built a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment said Kinaxo’s co-founder and world-reknown cancer researcher Prof. Dr Axel Ullrich. „The integration of the leading drug discovery capability will implement Evotec as a driver towards personalised medicine in the future." Kinaxo offers state-of-the-art quantitative techniques to analyse drug effects on a cell’s phosphoproteome or kinome to pharmaceutical companies and eases preclinical assessment of adrug candidate's efficacy, mode-of-action, target population and off-target effects. The company, which relies on three platform technologies, currently is running partnerships with BMS, AstraZeneca, Roche, Jansen Pharmaceutical, Takeda, BayerVital, or Boehringer Ingelheim. Kinaxo’s Cellular Target Profiling® platfom uncovers the protein binding partners of compounds with unknown mode-of-action with help of label-free quantitative mass spectrometry techniques developed at Martinsried-based Max-Planck-Institute of Biochemistry such as SILAC or iTraq. Its KinAffinity® platform gives Evotec the capability to screen for a drug candidate’s interactions with all 340 cellular protein kinases, the most important class of targeted cancer drugs.The third proteomics application termed PhosphoScout® provides insight in a drug’s mode-of-action in vivo by identifying its interference with cellular signal pathways. On the other hand it provides biomarkers for stratification of drug responders. "Through the acquisition of Kinaxo, Evotec gains access to a highly innovative technology base in drug discovery," said Dr Werner Lanthaler, Chief Executive Officer of Evotec AG."



The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...



Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...



Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...



German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....



Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...



Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...


Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...



Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...



Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...



Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CYTOS1.10 CHF7.84%
  • WILEX3.40 EUR6.25%
  • 4SC1.28 EUR4.07%


  • BIOFRONTERA2.36 EUR-6.35%
  • FORMYCON29.79 EUR-6.35%


  • 4SC1.28 EUR52.4%
  • VITA 346.59 EUR18.7%
  • CO.DON3.11 EUR17.8%


  • MOLOGEN5.10 EUR-35.4%
  • CYTOS1.10 CHF-18.5%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA100.80 CHF2511.4%
  • CYTOS1.10 CHF746.2%
  • FORMYCON29.79 EUR328.6%


  • MOLOGEN5.10 EUR-54.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.36 EUR-29.6%

No liability assumed, Date: 23.04.2015

Current issue

All issues